Scinai Immunotherapeutics Ltd (NASDAQ:SCNI) — Market Cap & Net Worth
Market Cap & Net Worth: Scinai Immunotherapeutics Ltd (SCNI)
Scinai Immunotherapeutics Ltd (NASDAQ:SCNI) has a market capitalization of $1.33 Million ($1.33 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30319 globally and #6089 in its home market, demonstrating a -4.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Scinai Immunotherapeutics Ltd's stock price $0.34 by its total outstanding shares 3959792 (3.96 Million). Review debt load of Scinai Immunotherapeutics Ltd to assess the company's total debt and financial obligations.
Scinai Immunotherapeutics Ltd Market Cap History: 2015 to 2026
Scinai Immunotherapeutics Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.57 Billion to $1.33 Million (-48.41% CAGR).
Index Memberships
Scinai Immunotherapeutics Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #900 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2858 of 3165 |
Weight: Scinai Immunotherapeutics Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Scinai Immunotherapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Scinai Immunotherapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.15x
Scinai Immunotherapeutics Ltd's market cap is 2.15 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $13.25 Million | $658.00K | $4.80 Million | 20.13x | 2.76x |
| 2025 | $2.82 Million | $1.31 Million | -$8.31 Million | 2.15x | N/A |
Competitor Companies of SCNI by Market Capitalization
Companies near Scinai Immunotherapeutics Ltd in the global market cap rankings as of June 18, 2026.
Key companies related to Scinai Immunotherapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Scinai Immunotherapeutics Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Scinai Immunotherapeutics Ltd's market cap moved from $1.57 Billion to $ 1.33 Million, with a yearly change of -48.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.33 Million | -52.68% |
| 2025 | $2.82 Million | -78.71% |
| 2024 | $13.25 Million | -43.78% |
| 2023 | $23.56 Million | -79.90% |
| 2022 | $117.21 Million | -87.40% |
| 2021 | $930.55 Million | -16.37% |
| 2020 | $1.11 Billion | -69.75% |
| 2019 | $3.68 Billion | +94.76% |
| 2018 | $1.89 Billion | -11.01% |
| 2017 | $2.12 Billion | +60.00% |
| 2016 | $1.33 Billion | -15.40% |
| 2015 | $1.57 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Scinai Immunotherapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.33 Million USD |
| MoneyControl | $1.33 Million USD |
| MarketWatch | $1.33 Million USD |
| marketcap.company | $1.33 Million USD |
| Reuters | $1.33 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's s… Read more